Short Interest in Hyperfine, Inc. (NASDAQ:HYPR) Rises By 59.7%

Hyperfine, Inc. (NASDAQ:HYPR) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 2,140,000 shares, a growth of 59.7% from the January 31st total of 1,340,000 shares. Currently, 3.8% of the shares of the company are short sold. Based on an average trading volume of 301,800 shares, the days-to-cover ratio is presently 7.1 days.

Hyperfine Price Performance

NASDAQ HYPR remained flat at $0.93 on Tuesday. 513,030 shares of the company’s stock were exchanged, compared to its average volume of 424,005. Hyperfine has a 12 month low of $0.76 and a 12 month high of $1.90. The firm has a market cap of $67.84 million, a price-to-earnings ratio of -1.63 and a beta of 0.92. The firm’s 50 day moving average price is $1.06 and its 200-day moving average price is $1.01.

Hedge Funds Weigh In On Hyperfine

Several large investors have recently made changes to their positions in HYPR. Virtu Financial LLC bought a new stake in Hyperfine during the 4th quarter valued at approximately $25,000. Graypoint LLC purchased a new stake in Hyperfine during the 4th quarter valued at approximately $44,000. Renaissance Technologies LLC raised its position in shares of Hyperfine by 32.9% during the fourth quarter. Renaissance Technologies LLC now owns 212,300 shares of the company’s stock valued at $187,000 after buying an additional 52,500 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Hyperfine by 18.7% in the third quarter. Geode Capital Management LLC now owns 624,520 shares of the company’s stock worth $675,000 after buying an additional 98,335 shares in the last quarter. 15.03% of the stock is currently owned by hedge funds and other institutional investors.

Hyperfine Company Profile

Hyperfine, Inc, a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors.